NCT02807272 2024-07-17
CMML/AML
Kura Oncology, Inc.
Phase 2 Completed
Clinical Trials
35 trialsNCT02383927 2024-07-11
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Kura Oncology, Inc.
Phase 2 Completed
NCT02464228 2024-06-26
PTCL
Kura Oncology, Inc.
Phase 2 Completed
NCT03719690 2024-06-21
AIM-HN/SEQ-HN
Kura Oncology, Inc.
Phase 2 Completed
NCT00026104 2020-10-30
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00082888 2020-04-13
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00082810 2018-11-01
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00005832 2015-11-17
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00047216 2015-07-23
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
University Health Network, Toronto
Phase 2 Completed
NCT01361464 2015-04-08
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00602771 2014-10-09
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00281957 2014-05-20
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006376 2013-12-04
R115777 in Treating Patients With Advanced Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00070525 2013-10-08
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005848 2013-07-11
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Fox Chase Cancer Center
Phase 2 Completed
NCT00052728 2013-06-19
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00049114 2013-06-06
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00060125 2013-06-05
Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00047190 2013-06-04
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00055757 2013-06-04
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025038 2013-04-11
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00058097 2013-04-09
Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00027872 2013-03-25
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077363 2013-02-27
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005843 2013-02-11
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00050141 2013-02-01
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00093418 2013-01-15
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005041 2012-11-09
R115777 in Treating Patients With Relapsed Small Cell Lung Cancer
NYU Langone Health
Phase 2 Completed
NCT00012350 2012-10-23
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00005833 2012-06-14
S9923 R115777 in Treating Patients With Advanced Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00209989 2011-11-24
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
Institut Claudius Regaud
Phase 2 Completed
NCT00005989 2011-08-04
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Mayo Clinic
Phase 2 Completed
NCT00354146 2011-02-01
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00048503 2010-04-27
Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed